June 14, 2016 : DCMS #297

DISASTERS AVERTED — Near Miss Case Studies

Put the Needle in the Pill Box

EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners

Dr. A. Paul Chous Part 1, The Significance of Anti-VEGF Agents

HOMERUN SLIDES — Great Clinical Presentation Highlights

 Pharmacologic Management of Type 2 Diabetes Part 1

CLINICAL GEMS — The Best from Diabetes Texts

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #28: Insulin Gene Expression and Biosynthesis Part 4 of 6

MOST POPULAR ARTICLES OF THE MONTH

#1 Metabolic Surgery: Standard Treatment Option for Type 2?
#2 Blood-Pressure Drug Could Be A Possible Type 1 Diabetes Cure
#3 Why the New Food Label? What to Tell Your Patients

We are at the ADA in New Orleans and as I was looking over the posters, there was a whole section focused on Gene Expression and Biosynthesis. There were multiple small population projects on what might cause the mutations and proposed mechanisms to fix  or prevent the problems that these mutations often bring.

A lot of what they covered was very complex and I had to look up a few terms. Over the next few weeks we will be sharing this information with you, but for now, getting a basic understanding of these concepts and how this newer science works may be a good reason to check out this week’s Clinical Text on translation and translocation.

Dave Joffe
Editor-in-chief

Male, 32 years of age. Works erratic hours. Recently came up with a plan of how to remember to take his meds. He started setting up and taking his pill box with him. He has succeeded at taking his medications and taking them on time…all except his injectable medications.

In part 1 of this Exclusive Interview, Dr. Paul Chous discusses the significance of studies around the three anti-VEGF injections that seek to determine which is the best.

In this week’s Homerun Slides, the Canadian Diabetes Association’s guidelines for the pharmacologic treatment of type 2 diabetes, which dictate that the choice of therapy depends on glycemia.

Insulin biosynthesis: the previous section outlines that insulin gene transcription is a highly controlled process. The product of this process, pre-proinsulin mRNA, is unusually stable in pancreatic beta cells and it is further stabilized as glucose concentrations increase. As such, there is normally an abundant source of preproinsulin mRNA in the beta-cell cytosol available for translation.

New guidelines cite effectiveness, cost efficiency, and safety as reasons to consider procedure.

A common blood pressure drug is showing new promise to help treat and cure type 1 diabetes.

New FDA nutrition facts label aims to make it easier for consumers to make informed choices about what they’re eating.